[The pilot study of intravitreal injection of triamcinolone acetonide for treatment of retinal detachment with choroidal detachment].
OBJECTIVE
To evaluate the efficiency and safety of intravitreal injection of triamcinolone acetonide for treatment of retinal detachment with choroidal detachment.


METHODS
13 the patients (13 eyes) of retinal detachment with choroidal detachment were chosen and triamcinolone acetonide 0.1 ml (4 mg) were administrated via intravitreal injection through pars plana. The therapeutic effects on uveitis and choroidal detachment was analyzed. The retinal reattachment surgery was performed five to ten days after the injection.


RESULTS
all 13 patients receiving triamcinolone acetonide demonstrated alleviated uveitis to some degree. The rate of retinal holes detection increased from 2/13 pre-injection to 7/13 post-operation. Choroidal detachment disappeared in most of cases within 10 days triamcinolone acetonide injection. Five eyes underwent scleral buckling, 6 eyes underwent with vitrectomy, and 2 patients abandoned surgery. The average follow up after surgery was 4 and half months. All eyes received with triamcinolone acetonide injection and surgery had retinal reattached successfully and no side effects were detected.


CONCLUSIONS
Intravitreal injection of triamcinolone acetonide was an effective and safe method to treat choroidal detachment and alleviate uveitis. The injection simplified surgery procedure and improve the success rate of retinal detachment.
Duan
An-li
AL
Beijing Tongren Ophthalmic Center, Capital University of Medical Sciences, Beijing 100730, China.
Wang
Jing-zhao
JZ
Wang
Ning-li
NL
D000328:Adult; D000368:Aged; D015862:Choroid Diseases / Q000188:drug therapy* / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012163:Retinal Detachment / Q000188:drug therapy* / Q000601:surgery; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000627:therapeutic use*; D014822:Vitreous Body / Q000187:drug effects*
D014222:Triamcinolone Acetonide